A multidisciplinary team of scientists led by The Wistar Institute has been awarded a more than $12 million NCI P01, a five-year grant that includes a cross section of researchers from disciplines and institutions throughout the country.
FDA approved Elahere (mirvetuximab soravtansine-gynx) for adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.
